Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
An exciting industry consisting of companies who develop new drugs to combat such diseases as cancer and other life-threatening diseases. Some may also participate in gene therapy. These firms either bring new drugs to the market themselves (which is a grueling process) or they sell their technology to bigger pharmaceutical companies.
|
| Totals |
Company |
Industry |
| Sales: |
$124.9 Mil |
$93,638.6 Mil |
| Market Cap: |
$2,519.4 Mil |
$517,548.6 Mil |
| Analysts Recommendation: |
Strong Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
620.7% |
42.3% |
| Estimated Revenue: |
77.6% |
104.1% |
| Historic Earnings: |
N/A |
(35.9%) |
| Estimated Earnings: |
N/A |
7.8% |
| Stock Price (1 Year): |
(46.4%) |
38.0% |
| Cash per Share: |
(58.6%) |
17.4% |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
N/A |
30.0 |
| Price-to-Sales: |
13.6 |
N/A |
| Price-to-Book: |
7.5 |
4.4 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$2,519.4 Mil |
$11,251.1 Mil |
| Operations |
| Net Margin: |
(136.0%) |
(1,230.9%) |
| Gross Margin: |
92.7% |
75.5% |
| Return on Equity: |
(.9) |
(.3) |
| Return on Assets: |
(.8) |
(.3) |
| Balance Sheet |
| Current Ratio: |
7.6 |
5.0 |
| Quick Ratio: |
7.5 |
4.6 |
| Cash Ratio: |
7.0 |
3.9 |
| Debt-to-Equity: |
.1 |
1.0 |
| Interest Coverage: |
N/A |
1.7 |
| Technicals |
| Relative-Strength Index: |
84.2 |
46.1 |
|
|
|
